---
schema_version: "secwatch.filing_event.v1"
accession: "0001860782-23-000101"
form_type: "8-K"
ticker: null
cik: "0001860782"
company_name: "2seventy bio, Inc."
filed_at: "2023-09-12T23:59:59+00:00"
generated_at: "2026-06-10T21:23:15.622387+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# 2seventy bio cuts workforce 40%, CEO to step down, Abecma revenue guidance lowered

## Summary
- Workforce reduction of ~40% (176 roles); expects $130M+ savings in 2024-2025 and $9M one-time costs; cash runway into at least 2026.
- CEO Nick Leschly to resign upon successor identification; plans to become Chairman. CFO Chip Baird promoted to COO.
- FY2023 Abecma U.S. revenue expected below prior $470-$570M guidance due to Q3 decline.
- bbT369 Phase I continues; SC-DARIC33 on clinical hold; two new programs (MUC-16, MAGE-A4 TCR) approaching IND in 2023.
- Expanded JW Therapeutics collaboration to include solid tumor and autoimmune CAR T programs.

## SEC filing metadata
- accession: 0001860782-23-000101
- form_type: 8-K
- cik: 0001860782
- company_name: 2seventy bio, Inc.
- filed_at: 2023-09-12T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.05, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860782/000186078223000101/0001860782-23-000101-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860782/000186078223000101/tvst-20230908.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001860782-23-000101
- JSON: https://secwatch.observer/filing/0001860782-23-000101.json
- Plain text: https://secwatch.observer/filing/0001860782-23-000101.txt

## Key facts
- Executive change
  Nick Leschly departed as president and chief executive officer at 2seventy bio, Inc..
  - Action: resign
  - Role: president and chief executive officer
  source text: Nick Leschly, the Company’s president and chief executive officer, notified the Company’s board of directors of his intent to resign as president and chief executive officer upon the Board’s identification of his successor.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860782/000186078223000101/0001860782-23-000101-index.htm
- Executive change
  William D. Baird, III was appointed as chief operating officer at 2seventy bio, Inc..
  - Action: appointed
  - Role: chief operating officer
  source text: the board of directors of the Company appointed William D. Baird, III as the chief operating officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860782/000186078223000101/0001860782-23-000101-index.htm
- Restructurings & Charges
  2seventy bio, Inc. announced a restructuring with charges of approximately $9 million (approximately 40% of its workforce).
  - Type: restructuring
  - Charge: approximately $9 million
  - Headcount: approximately 40% of its workforce
  source text: On September 12, 2023, 2seventy bio, Inc. (the “Company”) announced a strategic restructuring, including plans to reduce its workforce by approximately 40%. The Company expects this workforce reduction and restructuring will preserve its cash runway into 2026 and will be substantially completed by the fourth quarter of 2023. In connection with this workforce reduction and restructuring, the Company expects to incur one-time costs of approximately $9 million, primarily in the third quarter of 2023, relating to severance and retention packages and related benefits.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860782/000186078223000101/0001860782-23-000101-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.